EYE.ASX: Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

Stock	Nova EYE Medical Ltd (EYE.ASX)
Release Time	29 Jul 2026, 11:03 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Nova Eye Medical Ltd Reports Strong Sales Growth and Positive EBITDA

Key Points

FY26 total sales of US$23.7 million, up 26% year-over-year
Sales excluding China reached US$22.7 million, up 29% year-over-year
Achieved positive EBITDA of US$0.14 million in H2FY26
Group cash outflow from operations reduced to A$0.2 million for the quarter
FY27 sales, excluding China, expected to be between US$26 million and US$31 million

Full Summary

Nova Eye Medical Ltd reported total sales of US$23.7 million for the year ended 30 June 2026, marking a 26% increase year-over-year. Sales excluding China reached US$22.7 million, up 29% year-over-year. The company achieved a positive EBITDA of US$0.14 million in the second half of FY26, ahead of guidance. Group cash outflow from operations reduced to A$0.2 million for the quarter. The company expects sales, excluding China, to be between US$26 million and US$31 million in FY27, with positive EBITDA expected.

Guidance

FY27 sales, excluding China, expected to be between US$26 million and US$31 million

Outlook

Nova Eye Medical Ltd expects continued growth in FY27, with positive EBITDA anticipated. The company's cash position and existing debt facilities are expected to support these growth targets.